Batavia Bio Processing

Batavia Biosciences is a specialized Contract Development and Manufacturing Organization (CDMO) focused on accelerating the development of viral vaccines, viral vectors, and recombinant proteins. Founded in 2010 and headquartered in Leiden, Netherlands, the company provides end-to-end biopharmaceutical services ranging from DNA cloning and cell line generation to clinical and commercial GMP manufacturing. Batavia utilizes proprietary technology platforms such as HIP-Vax for high-yield vaccine production and STEP-Vax for protein expression to reduce costs and development timelines. In 2021, the South Korean conglomerate CJ CheilJedang acquired a majority stake in the company, completing a full 100% acquisition in early 2026 to integrate Batavia into its global healthcare and biologics strategy. The company operates facilities in the Netherlands and the United States, serving a global client base that includes major pharmaceutical companies, biotech startups, and non-profit organizations like the Bill & Melinda Gates Foundation.